The longevity researcher argues the FDA system has grown too slow and costly, saying it favors big drugmakers. He offers this as the reason reform efforts emerged.
Recap by typeshit. Post by Matt Kaeberlein on X.
Experts debate how regulators should separate real patient customization from mass-produced copies, citing recent tirzepatide sterility recalls and impurity findings.
A legal walkthrough of the 503A rules behind the October 28 policy, the July advisory vote, and the HHS note that it may revisit the policy if safety signals appear.
The recall came after an FDA warning letter. The Regulatory Review uses it to dig into how compounded GLP-1s stayed on sale after shortages officially ended.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
The broadcaster shared a new picture for followers who asked how his diabetes medication is going, joking he might try out for the X Factor.
Trials show large weight loss on semaglutide, and medical attention is shifting to the health effects that come with it.
Loading…